Caribou Biosciences (CRBU) Stock Statistics & Valuation Metrics

Caribou Biosciences has a market cap or net worth of $192.41M. The enterprise value is $177.55M.

Caribou Biosciences has 99,180,570 shares outstanding. The number of shares has decreased by -2.65% in one year.

Caribou Biosciences’s return on equity (ROE) is -1.21 and return on invested capital (ROIC) is -89.77%.

The current PE Ratio of Caribou Biosciences is ―. Caribou Biosciences’s PEG ratio is 0.28.

In the last 12 months, Caribou Biosciences had revenue of 11.16M and earned -148.13M in profits. Earnings per share was -1.59.

In the last 12 months, operating cash flow was -101.25M and capital expenditures -389.00K, giving a free cash flow of -101.64M billion.

Caribou Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―

Caribou Biosciences upcoming earnings date is Aug 11, 2026, After Close (Confirmed).

Caribou Biosciences as a current ratio of 5.71, with Debt / Equity ratio of 26.41%

In the past 12 months, Caribou Biosciences has paid -550.00K in taxes.

Caribou Biosciences EV to EBITDA ratio is -1.13, with an EV/FCF ratio of -1.45.

Caribou Biosciences has $117.63M in cash and marketable securities with $26.95M in debt, giving a net cash position of $90.68M billion.

Gross margin is -117.33%, with operating margin of -1220.49%, and net profit margin of -1327.40%.

The average price target for Caribou Biosciences is $8.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy